This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Sign in
Sign in
Sign out

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Explore Content

Learn about the efficacy and safety of Somavert, its tumour impact and its effect on co-morbidity management through clinical and real world data

The acromegaly disease activity tool designed to help monitor your patients

Advice and support services to help you and your patients optimise your experience with Somavert about the efficacy and safety of Somavert through clinical and real world data

Learn about funding and reimbursement England, Scotland, Wales and Northern Ireland

Watch and listen to acromegaly experts talk about various topics in the disease area as well as recordings from our National Nurse Meeting and the Acromegaly co-morbidity series

Click here for Somavert® (pegvisomant) Prescribing Information. Adverse event reporting information can be found at the bottom of the page.

Somavert is used in the treatment of adult patients with acromegaly who have had an inadequate response to surgery and/or radiation therapy and in whom an appropriate medical treatment with somatostatin analogues did not normalise IGF-I concentrations or was not tolerated.

Somavert reimbursement in Wales, Scotland & Northern Ireland

Somavert is reimbursed by AWMSG, SMC and NI Formulary

Wales​​​​​​​1

In November 2017, the All Wales Medicines Strategy Group recommended Somavert as a third-line treatment of acromegaly in adults.
​​​​​​​
Somavert is recommended as an option for use within NHS Wales for the treatment of adult patients with acromegaly who have had an inadequate response to surgery and/or radiation therapy and in whom an appropriate medical treatment with SSAs didn’t normalise IGF-I concentrations or was not tolerated.

This recommendation applies only in circumstances where the approved Wales Patient Access Scheme (WPAS) is utilised or where the list/contract price is equivalent or lower than the WPAS price.

Scotland​​​​​​​2

Following a second resubmission considered under the ultra-orphan process, pegvisomant (Somavert) is accepted for use within NHS Scotland.

For the treatment of adult patients with acromegaly who have had an inadequate response to surgery and/or radiation therapy and in whom an appropriate medical treatment with SSAs did not normalise IGF-I concentrations or was not tolerated.
​​​​​​​
SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost effectiveness of pegvisomant and is contingent upon the continuing availability of the PAS in NHS Scotland or a list price that is equivalent or lower. This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.

Northern Ireland​​​​​​​3

In Northern Ireland, pegvisomant (Somavert) is accepted for use
​​​​​​​
For the treatment of adult patients with acromegaly who have had an inadequate response to surgery and/or radiation therapy and in whom an appropriate medical treatment with SSAs did not normalise IGF-I concentrations or was not tolerated
​​​​​​​
This advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost effectiveness of pegvisomant and is contingent upon the continuing availability of the PAS in Northern Ireland or a list price that is equivalent or lower

The Somavert prescribing guide

Find information on funding, initiation, homecare and follow-up

Download the guide

Explore more

Contact us 

To find out more about ACRODAT, supporting your patients or to order starter kits

Contact us

Homecare services 

We offer a range of services that help your patients at home with medication delivery and face-to-face support

Learn more

Header

Abbrevations:

IGF-1=Insulin-like growth factor
NI formulation=Northern Ireland formulation
AWMSG=All Wales Medicine Stratergy Group
SMC=Scottish Medicines consortium


References 

​​​​​​​1. All Wales Medicines Strategy Group. November 2017. Available here (date accessed: January 2022)
2. Scottish Medicines Consortium. November 2017. Available here (date accessed: January 2022)
3. Northern Ireland Formulary. January 2018. Available here (date accessed: January 2022)

PP-SOM-GBR-1126. January 2022

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021

Yes

No

OK, We will need you to sign in before we can determine if you are aligned with a Pfizer promotional colleague.This is an interstitial message to prompt a HCP before they login.

If you have already registered with pfizerpro.co.uk and select ‘yes’, you will be directed to the sign-in page where you will be required to enter your username and password.

Would you like to register or sign in now?